measurable residual disease
Showing 1 - 25 of >10,000
Digital Droplet PCR in Early Period After Allo-HSCT to Predict
Completed
- Measurable Residual Disease
- Digital Droplet PCR
-
Hangzhou, Zhejiang, ChinaThe First Hospital of Zhejiang Medical Colleage Zhejiang Univers
Aug 17, 2023
Measurable Residual Disease in Acute Myeloid Leukemia as
Terminated
- Leukemia, Myeloid, Acute
- Measurable residual disease measured by flow cytometry
-
Heidelberg, BW, GermanyUniversity Hospital Heidelberg
Sep 12, 2022
MDS Trial in Saint Louis (DEC-C, MyeloSeq-HD)
Recruiting
- Myelodysplastic Syndromes
- DEC-C
- MyeloSeq-HD
-
Saint Louis, MissouriWashington University School of Medicine
Jan 18, 2023
AML, Adult, Minimal Residual Disease Trial (MRD assessment)
Not yet recruiting
- AML, Adult
- Minimal Residual Disease
- MRD assessment
- (no location specified)
Oct 13, 2023
Acute Myeloid Leukemia, Leukemia, Leukemia, Myeloid Trial in Boston (Cytokine Induced Memory-like Natural Killer Cells,
Not yet recruiting
- Acute Myeloid Leukemia
- +5 more
- Cytokine Induced Memory-like Natural Killer Cells
- Interleukin-2
-
Boston, Massachusetts
- +1 more
Nov 14, 2023
Acute Myeloid Leukemia Trial in Los Angeles, San Francisco (Azacitidine, Tagraxofusp-erzs)
Not yet recruiting
- Acute Myeloid Leukemia
- Azacitidine
- Tagraxofusp-erzs
-
Los Angeles, California
- +1 more
Jan 31, 2023
Mixed Phenotype Acute Leukemia (MPAL), Measurable Residual Disease (MRD) Trial in Baltimore (BLINCYTO (Blinatumomab))
Recruiting
- Mixed Phenotype Acute Leukemia (MPAL)
- Measurable Residual Disease (MRD)
- BLINCYTO (Blinatumomab)
-
Baltimore, MarylandGreenebaum Cancer Center at University of Maryland Medical Cente
Apr 18, 2022
Clinical Pathways for Newly Diagnosed Multiple Myeloma
Not yet recruiting
- Multiple Myeloma
- Multiple Myeloma Without Mention of Remission
- Multiple Myeloma Pathway
- +2 more
- (no location specified)
Nov 27, 2023
AML Patients After Stem Cell Transplant to Understand Relapse
Recruiting
- Acute Myeloid Leukemia in Remission
- Prospective determination of the clinical utility of measurable residual disease (MRD) testing
-
Duarte, California
- +3 more
Dec 7, 2022
Acute Lymphoblastic Leukemia Trial in Bergamo, Monza (PTG-CARCIK-CD19)
Recruiting
- Acute Lymphoblastic Leukemia
- PTG-CARCIK-CD19
-
Bergamo, Italy
- +1 more
Feb 12, 2022
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
Recruiting
- Acute Myeloid Leukemia
- +3 more
- Cytarabine
- +4 more
-
Birmingham, Alabama
- +8 more
Jan 24, 2023
Acute Myeloid Leukemia Trial in Worldwide (Cyclophosphamide-Fludarabine (Cy/Flu), oNKordĀ®)
Recruiting
- Acute Myeloid Leukemia
- Cyclophosphamide-Fludarabine (Cy/Flu)
- oNKordĀ®
-
Ghent, Belgium
- +9 more
Jun 15, 2022
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
Recruiting
- Acute Myeloid Leukemia
- +3 more
- Azacitidine
- +5 more
-
Greenwich, Connecticut
- +27 more
Dec 30, 2022
Multiple Myeloma Trial in Chicago (Screening Phase, Discontinuation Phase)
Recruiting
- Multiple Myeloma
- Screening Phase
- Discontinuation Phase
-
Chicago, IllinoisUniversity Of Chicago Medicine Comprehensive Cancer Center
Jan 8, 2021
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Arising
Not yet recruiting
- Acute Myeloid Leukemia
- +4 more
- Azacitidine
- +6 more
- (no location specified)
Nov 8, 2022
NPMc+ AML Trial in Hong Kong (Oral Arsenic Trioxide Formulation)
Recruiting
- NPMc+ AML
- Oral Arsenic Trioxide Formulation
-
Hong Kong, Hong KongThe University of Hong Kong
Dec 29, 2020
Leukemia, Myeloid, Acute Trial in Spain (Idarubicin, Ara-C, G-CSF)
Recruiting
- Leukemia, Myeloid, Acute
- Idarubicin
- +5 more
-
Badalona, Barcelona, Spain
- +14 more
Jul 30, 2021
Minimal Residual Disease Using Multi-omics Approach
Not yet recruiting
- Pancreatic Ductal Adenocarcinoma
- Blood collection and Pancreatic ductal adenocarcinoma minimal residual disease detection test
-
Shanghai, ChinaDepartment of Pancreatic and Hepatobiliary Surgery, Fudan Univer
Nov 29, 2023
Minimally Residual of Esophageal Cancer 001
Recruiting
- Esophageal Carcinoma
- Minimal Residual Disease
-
Shijiazhuang, Hebei, ChinaFourth Hospital of Hebei Medical University
Jul 17, 2023
Renal Cell Carcinoma Trial in Birmingham (Pembrolizumab injection)
Not yet recruiting
- Renal Cell Carcinoma
- Pembrolizumab injection
-
Birmingham, AlabamaUniversity of Alabama at Birmingham
Aug 20, 2023
HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy Trial (SHR-A1811,
Not yet recruiting
- HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
- SHR-A1811
- Trastuzumab Emtansine
- (no location specified)
Nov 7, 2023
B-Cell Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia Trial in Tampa (Tecartus)
Recruiting
- B-Cell Lymphoblastic Leukemia
- Acute Lymphoblastic Leukemia
-
Tampa, FloridaMoffitt Cancer Center
Nov 28, 2023